CYP3A5 and neuropathy: In contrast, molecular markers, including polymorphisms in the hepatic vincristine metabolizer CYP3A5, displayed great promise in predicting increased incidence and severity of neuropathy; however, further studies are warranted to assess its use in treatment prediction.